Substance / Medication

Orphenadrine citrate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Myositis

Tetanus

Infection caused by Clostridium tetani

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Development and Validation of Chromatographic Methods for Simultaneous Determination of Paracetamol, Orphenadrine Citrate and Caffeine in Presence of P-aminophenol; Quantification of P-aminophenol Nephrotoxic Impurity Using LC-MS/MS.

Boltia Shereen A, Soudi Aya T, Elzanfaly Eman S et al. · J Chromatogr Sci · 2020

PMID: 31812988Observational

Validated stability-indicating reversed-phase-HPLC method for simultaneous determination of orphenadrine citrate, caffeine and aspirin.

Darwish Khaled, Salama Ismail, Mostafa Samia et al. · Chem Pharm Bull (Tokyo) · 2012

PMID: 23124566Observational

Acute adverse cutaneous reaction after the concomitant use of venlafaxine and orphenadrine citrate plus paracetamol in a depressed patient.

Papadimitriou G N, Theleritis C G, Papageorgiou C C et al. · J Eur Acad Dermatol Venereol · 2006

PMID: 16922966Case Report

Development of UV-Chemometric techniques for resolving the overlapped spectra of aspirin, caffeine and orphenadrine citrate in their combined pharmaceutical dosage form.

El-Adl Sobhy M, Mattar Amr A, El-Abassy Omar M et al. · BMC Chem · 2025

PMID: 40114249OtherFull text (PMC)

Exploitation of multi-walled carbon nanotubes/Cu(ii)-metal organic framework based glassy carbon electrode for the determination of orphenadrine citrate.

Kammoun Ahmed K, Abdelrahman Mona H, Khayyat Ahdab N et al. · RSC Adv · 2023

PMID: 37876650OtherFull text (PMC)

Transient electrical alternans in a patient with sinus tachycardia attributed to orphenadrine citrate ingestion.

Watt Euan, Peckler Bradley · Emerg Med Australas · 2022

PMID: 35640918Other

Effect of Genetic Algorithm-Based Wavelength Selection as a Preprocessing Tool on Multivariate Simultaneous Determination of Paracetamol, Orphenadrine Citrate, and Caffeine in the Presence of p-Aminophenol Impurity.

Boltia Shereen A, Soudi Aya T, Elzanfaly Eman S et al. · J AOAC Int · 2020

PMID: 31277724Other

Development of a capillary electrophoresis method for the determination of orphenadrine citrate in tablets in the presence of paracetamol.

Haj-Ali Dana N, Hamdan Imad I · Saudi Pharm J · 2010

PMID: 23960732OtherFull text (PMC)

Determination of paracetamol and orphenadrine citrate in pharmaceutical tablets by modeling of spectrophotometric data using partial least-squares and artificial neural networks.

Sratthaphut Lawan, Ruangwises Nongluck · Yakugaku Zasshi · 2007

PMID: 17917430Other

Therapeutic response of benzodiazepine, orphenadrine citrate and occlusal splint association in TMD pain.

Rizzatti-Barbosa Célia M, Martinelli Denise A, Ambrosano Gláucia M B et al. · Cranio · 2003

PMID: 12723857Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Orphenadrine citrate (substance)
SNOMED CT: 387167001
UMLS CUI: C0029310

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.